SCHEMBL1110440

SCHEMBL1110440

C1=CN[C](N2CCOCC2)N=C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.35
MAPT P10636 2/20 0.35
POLB P06746 3/20 0.34
PIK3CA P42336 3/20 0.33
HTT P42858 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CB P42338 1/20 0.33
ALDH1A1 P00352 3/20 0.33
GAA P10253 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PIK3R1 P27986 2/20 0.33
MTOR P42345 2/20 0.33
TP53 P04637 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28691975 0.71 POLB (0.33) LMNAMAPTPOLBPIK3CAHTT
SCHEMBL2321070 0.65 LMNA (0.36) LMNAMAPTPOLBPIK3CAHTT
SCHEMBL28065730 0.63 ALDH1A1 (0.38) LMNAMAPTPOLBHTTALDH1A1
SCHEMBL28646855 0.61 MAPT (0.52) LMNAMAPTHTTALDH1A1GAA
SCHEMBL10437894 0.60 MAPT (0.36) LMNAMAPTPOLBPIK3CAHTT
SCHEMBL3739181 0.58 LMNA (0.36) LMNAMAPTPOLBHTTALDH1A1
SCHEMBL9093746 0.58 LMNA (0.71) LMNAMAPTPOLBPIK3CAHTT
SCHEMBL9424119 0.57 LMNA (0.62) LMNAMAPTPOLBHTTALDH1A1
SCHEMBL2815977 0.56 KMT2A (0.55) LMNAPOLBPIK3CAHTTALDH1A1
SCHEMBL28640180 0.56 LMNA (0.61) LMNAMAPTPIK3CAHTTPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US claimed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP claimed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO claimed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 LMNA 3223/4885MAPT 4383/4885POLB 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.